- Home
- CMPS vs FDMT Comparison
CMPS vs FDMT Comparison
Compare CMPS & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- FDMT
- Stock Information
- Founded
- CMPS 2020
- FDMT 2013
- Country
- CMPS United Kingdom
- FDMT United States
- Employees
- CMPS N/A
- FDMT N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- FDMT Health Care
- Exchange
- CMPS Nasdaq
- FDMT Nasdaq
- Market Cap
- CMPS 362.6M
- FDMT 420.7M
- IPO Year
- CMPS 2020
- FDMT 2020
- Fundamental
- Price
- CMPS $5.04
- FDMT $8.83
- Analyst Decision
- CMPS Strong Buy
- FDMT Strong Buy
- Analyst Count
- CMPS 7
- FDMT 9
- Target Price
- CMPS $30.67
- FDMT $46.75
- AVG Volume (30 Days)
- CMPS 1.5M
- FDMT 804.9K
- Earning Date
- CMPS 10-31-2024
- FDMT 11-13-2024
- Dividend Yield
- CMPS N/A
- FDMT N/A
- EPS Growth
- CMPS N/A
- FDMT N/A
- EPS
- CMPS N/A
- FDMT N/A
- Revenue
- CMPS N/A
- FDMT $17,000.00
- Revenue This Year
- CMPS N/A
- FDMT N/A
- Revenue Next Year
- CMPS N/A
- FDMT $57.85
- P/E Ratio
- CMPS N/A
- FDMT N/A
- Revenue Growth
- CMPS N/A
- FDMT N/A
- 52 Week Low
- CMPS $4.05
- FDMT $7.32
- 52 Week High
- CMPS $12.75
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- CMPS 39.50
- FDMT 50.43
- Support Level
- CMPS $4.79
- FDMT $7.32
- Resistance Level
- CMPS $5.57
- FDMT $8.74
- Average True Range (ATR)
- CMPS 0.47
- FDMT 0.48
- MACD
- CMPS -0.00
- FDMT 0.19
- Stochastic Oscillator
- CMPS 40.74
- FDMT 82.97
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.